JP2011519867A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011519867A5 JP2011519867A5 JP2011507701A JP2011507701A JP2011519867A5 JP 2011519867 A5 JP2011519867 A5 JP 2011519867A5 JP 2011507701 A JP2011507701 A JP 2011507701A JP 2011507701 A JP2011507701 A JP 2011507701A JP 2011519867 A5 JP2011519867 A5 JP 2011519867A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- fatty acid
- item
- salt
- particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4962708P | 2008-05-01 | 2008-05-01 | |
| US61/049,627 | 2008-05-01 | ||
| PCT/US2009/042627 WO2009135190A2 (en) | 2008-05-01 | 2009-05-01 | Therapeutic calcium phosphate particles and methods of making and using same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011519867A JP2011519867A (ja) | 2011-07-14 |
| JP2011519867A5 true JP2011519867A5 (cg-RX-API-DMAC10.html) | 2012-06-21 |
Family
ID=41137579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011507701A Pending JP2011519867A (ja) | 2008-05-01 | 2009-05-01 | 治療用リン酸カルシウム粒子、ならびにその作製および使用方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20120128767A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP2285361A2 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2011519867A (cg-RX-API-DMAC10.html) |
| CN (1) | CN102014880A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2009135190A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2512454A2 (en) | 2009-12-16 | 2012-10-24 | Nod Pharmaceuticals, Inc. | Compositions and methods for oral drug delivery |
| WO2012145801A1 (en) * | 2011-04-29 | 2012-11-01 | Jagat Rakesh Kanwar | Nanoparticle |
| WO2014064710A1 (en) | 2012-10-22 | 2014-05-01 | Department Of Biotechnology | A process for the prepartion of non-viral vector for delivery of nucleic acids by mucosal route |
| CN103073645B (zh) * | 2012-12-31 | 2014-06-18 | 浙江大学 | 一种生物矿化的胰岛素蛋白纳米颗粒及其制备方法和应用 |
| GB201319548D0 (en) * | 2013-11-05 | 2013-12-18 | Medical Res Council | Amorphous magnesium-substituted calcium phosphate compositions and their uses |
| WO2015176031A2 (en) | 2014-05-15 | 2015-11-19 | Incube Labs, Llc | Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins |
| US10307350B2 (en) * | 2014-11-17 | 2019-06-04 | Nanotecmarin Gmbh | Morphogenetically active amorphous calcium polyphosphate nanoparticles for therapeutic applications |
| WO2018169954A1 (en) * | 2017-03-13 | 2018-09-20 | Sdg, Inc. | Lipid-based nanoparticles with enhanced stability |
| AU2021275223A1 (en) | 2020-05-20 | 2023-02-02 | Flagship Pioneering Innovations Vi, Llc. | Coronavirus antigen compositions and their uses |
| KR20230135585A (ko) | 2020-12-23 | 2023-09-25 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | 변형된 trem의 조성물 및 이의 용도 |
| EP4313109A1 (en) | 2021-03-31 | 2024-02-07 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| AR127073A1 (es) | 2021-09-17 | 2023-12-13 | Flagship Pioneering Innovations Vi Llc | Composiciones y métodos para producir polirribonucleótidos circulares |
| EP4419706A1 (en) | 2021-10-18 | 2024-08-28 | Flagship Pioneering Innovations VI, LLC | Compositions and methods for purifying polyribonucleotides |
| JP2025511756A (ja) | 2022-04-08 | 2025-04-16 | フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー | ワクチン及び関連する方法 |
| WO2023220083A1 (en) | 2022-05-09 | 2023-11-16 | Flagship Pioneering Innovations Vi, Llc | Trem compositions and methods of use for treating proliferative disorders |
| EP4544043A1 (en) | 2022-06-22 | 2025-04-30 | Flagship Pioneering Innovations VI, LLC | Compositions of modified trems and uses thereof |
| WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| EP4612296A1 (en) | 2022-10-31 | 2025-09-10 | Flagship Pioneering Innovations VI, LLC | Compositions and methods for purifying polyribonucleotides |
| WO2024102799A1 (en) | 2022-11-08 | 2024-05-16 | Flagship Pioneering Innovations Vi, Llc | Compositions and methods for producing circular polyribonucleotides |
| TW202430215A (zh) | 2022-12-14 | 2024-08-01 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 用於將治療劑遞送至骨之組成物和方法 |
| US20240238473A1 (en) | 2023-01-09 | 2024-07-18 | Beth Israel Deaconess Medical Center, Inc. | Recombinant nucleic acid molecules and their use in wound healing |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| TW202438515A (zh) | 2023-02-06 | 2024-10-01 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 免疫調節組合物及相關方法 |
| US20240293318A1 (en) | 2023-02-13 | 2024-09-05 | Flagship Pioneering Innovations Vii, Llc | Cleavable linker-containing ionizable lipids and lipid carriers for therapeutic compositions |
| KR20250151437A (ko) | 2023-02-17 | 2025-10-21 | 플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨 | 변형된 우라실을 포함하는 dna 조성물 |
| WO2024216128A1 (en) | 2023-04-12 | 2024-10-17 | Flagship Pioneering Innovations Vi, Llc | Trems for use in correction of missense mutations |
| WO2025006684A1 (en) | 2023-06-28 | 2025-01-02 | Flagship Pioneering Innovations Vi, Llc | Circular polyribonucleotides encoding antifusogenic polypeptides |
| KR20260044217A (ko) | 2023-07-25 | 2026-04-01 | 플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨 | Cas 엔도뉴클레아제 및 관련 방법 |
| WO2025042786A1 (en) | 2023-08-18 | 2025-02-27 | Flagship Pioneering Innovations Vi, Llc | Compositions comprising circular polyribonucleotides and uses thereof |
| WO2025054236A2 (en) | 2023-09-06 | 2025-03-13 | Flagship Pioneering Innovations Vii, Llc | Sars-cov-2 vaccine compositions and related methods |
| WO2025096807A2 (en) | 2023-10-31 | 2025-05-08 | Flagship Pioneering Innovations Vii, Llc | Novel therapeutic dna forms |
| KR20260113064A (ko) | 2023-11-14 | 2026-07-21 | 플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨 | 이온화 가능한 리피도이드 조성물 및 이의 치료적 용도 |
| WO2025194019A1 (en) | 2024-03-14 | 2025-09-18 | Flagship Pioneering Innovations Vii, Llc | Methods for treating liver fibrosis and non-alcoholic fatty liver disease |
| WO2025245188A2 (en) | 2024-05-21 | 2025-11-27 | Flagship Pioneering Innovations Vii, Llc | Methods of treating liver steatosis and non-alcoholic fatty liver disease |
| WO2025245111A1 (en) | 2024-05-22 | 2025-11-27 | Flagship Pioneering Innovations Vii, Llc | Immunoreceptor targeting proteins and related methods |
| CN118370728B (zh) * | 2024-06-24 | 2024-11-08 | 山东则正医药技术有限公司 | 一种glp-1ra载药纳米颗粒和制剂及其制备方法 |
| US20260000702A1 (en) | 2024-06-26 | 2026-01-01 | Flagship Pioneering Innovations Vii, Llc | Therapeutic circular dna forms |
| WO2026055547A1 (en) | 2024-09-06 | 2026-03-12 | Flagship Pioneering Innovations Vii, Llc | Dna compositions and related methods |
| WO2026055543A1 (en) | 2024-09-06 | 2026-03-12 | Flagship Pioneering Innovations Vii, Llc | Modified dna compositions and related methods |
| WO2026064313A1 (en) | 2024-09-17 | 2026-03-26 | Flagship Pioneering Innovations Vii, Llc | Rna compositions and related methods |
| WO2026085300A1 (en) | 2024-10-16 | 2026-04-23 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5219577A (en) | 1990-06-22 | 1993-06-15 | The Regents Of The University Of California | Biologically active composition having a nanocrystalline core |
| US5460831A (en) | 1990-06-22 | 1995-10-24 | The Regents Of The University Of California | Targeted transfection nanoparticles |
| US5460830A (en) | 1990-06-22 | 1995-10-24 | The Regents Of The University Of California | Biochemically active agents for chemical catalysis and cell receptor activation |
| US5462751A (en) | 1990-06-22 | 1995-10-31 | The Regeants Of The University Of California | Biological and pharmaceutical agents having a nanomeric biodegradable core |
| US6355271B1 (en) | 1999-02-03 | 2002-03-12 | Biosante Pharmaceuticals, Inc. | Therapeutic calcium phosphate particles and methods of manufacture and use |
| US20050260259A1 (en) * | 2004-04-23 | 2005-11-24 | Bolotin Elijah M | Compositions for treatment with glucagon-like peptide, and methods of making and using the same |
| WO2005039626A2 (en) * | 2003-10-27 | 2005-05-06 | Innodia Inc. | Use of hydroxylated amino acids for treating diabetes |
| EP1720520B1 (en) * | 2004-02-13 | 2010-06-09 | Nod Pharmaceuticals, Inc. | Particles comprising a core of calcium phosphate nanoparticles, a biomolecule and a bile acid, methods of manufacturing, therapeutic use thereof |
-
2009
- 2009-05-01 US US12/434,557 patent/US20120128767A1/en not_active Abandoned
- 2009-05-01 CN CN200980115262XA patent/CN102014880A/zh active Pending
- 2009-05-01 EP EP09739992A patent/EP2285361A2/en not_active Withdrawn
- 2009-05-01 WO PCT/US2009/042627 patent/WO2009135190A2/en not_active Ceased
- 2009-05-01 JP JP2011507701A patent/JP2011519867A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dan et al. | An update on pharmaceutical strategies for oral delivery of therapeutic peptides and proteins in adults and pediatrics | |
| Peng et al. | Challenges and opportunities in delivering oral peptides and proteins | |
| Cai et al. | Long-acting preparations of exenatide | |
| Gedawy et al. | Oral insulin delivery: existing barriers and current counter-strategies | |
| Thwala et al. | Emerging delivery platforms for mucosal administration of biopharmaceuticals: a critical update on nasal, pulmonary and oral routes | |
| Wong | Design of oral insulin delivery systems | |
| CN1993113B (zh) | 包含磷酸钙纳米颗粒核心，生物分子和胆汁酸的颗粒，其生产方法，其治疗用途 | |
| Nguyen et al. | The glucose-lowering potential of exendin-4 orally delivered via a pH-sensitive nanoparticle vehicle and effects on subsequent insulin secretion in vivo | |
| Lee et al. | Long-acting inhalable chitosan-coated poly (lactic-co-glycolic acid) nanoparticles containing hydrophobically modified exendin-4 for treating type 2 diabetes | |
| Chalasani et al. | A novel vitamin B12-nanosphere conjugate carrier system for peroral delivery of insulin | |
| AU2002349513B2 (en) | Medicinal compositions for nasal absorption | |
| KR100250390B1 (ko) | 마이크로입자의 경구전달 시스템 | |
| US20110189299A1 (en) | Pharmaceutical composition containing surface-coated microparticles | |
| Song et al. | Nanolayer encapsulation of insulin-chitosan complexes improves efficiency of oral insulin delivery | |
| Hwang et al. | Advances in oral macromolecular drug delivery | |
| JP5491119B2 (ja) | 薬物含有微粒子を含む医薬組成物およびその製造方法 | |
| EP3099293B1 (en) | Nanoencapsulation of hydrophilic active compounds | |
| JP2013525351A (ja) | ナノ粒子の医薬組成物 | |
| JP2008505919A5 (cg-RX-API-DMAC10.html) | ||
| US20180271792A1 (en) | Oral delivery of physiologically active substances | |
| Babu et al. | Developments in polymeric devices for oral insulin delivery | |
| JP2011519867A (ja) | 治療用リン酸カルシウム粒子、ならびにその作製および使用方法 | |
| WO2007093999A1 (en) | A gastro-retentive system for the delivery of macromolecules | |
| Cárdenas-Bailón et al. | Microencapsulation techniques to develop formulations of insulin for oral delivery: a review | |
| Fuhrmann et al. | Recent advances in oral delivery of macromolecular drugs and benefits of polymer conjugation |